Kodiak Sciences Inc (KOD) Stock Price, Quote & News

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degenerati...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 281 0850

Website: kodiak.com

Address:

1250 Page Mill Road, Palo Alto, United States

Swift_Trades Aug. 20 at 3:25 AM

$MRNA Similar upcoming potential catalysts... 😁 BioNTech ($BNTX) BNT113 mRNA immunotherapy for HPV16+ PD-L1+ head/neck cancer; Phase 3 interim PFS data expected later 2026. Geron ($GERN) imetelstat (telomerase inhibitor) for R/R myelofibrosis; Phase 3 OS interim analysis due 2H 2026. Kodiak ($KOD) Zenkuda/KSI-501 for wet AMD; Phase 3 DAYBREAK topline Sept 2026. Rank by likelihood of positive readout: 1. BNTX (Fast Track + prior signals, mRNA parallel to MRNA). 2. GERN (strong Phase 2 OS data). 3. KOD.

1 · Reply

spinusn27 Aug. 19 at 11:57 AM

$KOD $MRNA could be us in September. Good luck everyone. Lots of us have been here since $2.

0 · Reply

Stekli27 Aug. 18 at 4:00 PM

$KOD I expect some de-risking into DAYBREAK, just like we saw before the GLOW2 readout. If DAYBREAK comes in positive, I think this thing can explode..

1 · Reply

BB_88_ Aug. 17 at 3:37 PM

$KOD short tight stop day trade only

0 · Reply

Stekli27 Aug. 17 at 3:10 PM

$KOD Mid-August and the story is getting simple: September DAYBREAK, then December PEAK. Zenkuda already has a lot of Phase 3 validation behind it, KSI-501 is advancing into ALTO, and the pipeline keeps moving. Big few months ahead.👀

1 · Reply

BeeDecay Aug. 17 at 11:49 AM

$OCUL FDA rarely approves on ad-hoc outlier exclusions alone (e.g. $KOD / Intercept precedents). For $EYPT, it all comes down to the sister P3 LUCIA. If LUCIA hits its target: Strong pooled case (42% burden cut + CST drying) gives FDA a path to still approve. If LUCIA misses: DURAVYU wet AMD is dead. All in all this is the dream scenario for OCUL: TKI confirmed its mechanism, EYPT facing a trial drawback. If EYPT drops +50% I might nibble a bit for the first time. I give LUCIA a fair chance.

3 · Reply

BB_88_ Aug. 14 at 7:02 PM

$KOD expect fade in to close but could be wrong

0 · Reply

Stekli27 Aug. 14 at 6:34 PM

$KOD One month from DAYBREAK and the setup keeps getting stronger. Zenkuda already has four successful Phase 3 trials behind it, including non-inferiority in wet AMD. DAYBREAK incorporates the lessons from earlier studies with loading doses, treat-to-dryness and individualized q4–q24w dosing. Meanwhile, BLA preparation continues, ALTO is enrolling, PEAK is fully enrolled for Pivotal Analysis 1, and management just reconfirmed September for DAYBREAK. Nothing is guaranteed in biotech, but I like the risk/reward here more than ever. Now let the data speak. 👀🔥

1 · Reply

Ntense Aug. 14 at 2:01 PM

$KOD down 15% in a week on no news? Good opportunity to add.

0 · Reply

Stekli27 Aug. 14 at 1:44 PM

$KOD time to add more 👀

0 · Reply

3 Best Stocks With 75%+ Upside to Buy This Week, According to Analysts

ACHR CLSK

2026-08-16T14:14:32.000Z - 4 days ago

Kodiak Sciences reports Q2 EPS ($1.05), consensus (96c)

Aug 13, 2026, 4:00 PM EDT - 6 days ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results

Aug 13, 2026, 4:00 PM EDT - 6 days ago

Kodiak Sciences Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 6 days ago

Kodiak Sciences Quarterly report: Q2 2026

2026-08-10T20:51:09.000Z - 9 days ago

Kodiak enrolls first patients in phase 3 ALTO trial evaluating KSI-501

Aug 10, 2026, 4:43 PM EDT - 9 days ago

Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

2026-08-06T12:21:07.000Z - 14 days ago

Kodiak Sciences completes enrollment in first cohort of Phase 3 PEAK trial

Aug 6, 2026, 7:00 AM EDT - 14 days ago

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

2026-08-03T11:06:40.000Z - 17 days ago

Kodiak Sciences price target raised to $66 from $56 at JPMorgan

Jun 4, 2026, 11:40 AM EDT - 2 months ago

Kodiak Sciences Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:40 AM EDT - 2 months ago

Kodiak Sciences Slides: FY 2026

May 28, 2026, 6:09 PM EDT - 2 months ago

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

2026-05-11T16:59:46.000Z - 3 months ago

Kodiak Sciences upgraded to Buy from Neutral at Chardan

2026-05-07T21:46:34.000Z - 3 months ago

Kodiak Sciences reports Q1 EPS (94c), consensus ($1.01)

May 7, 2026, 4:00 PM EDT - 3 months ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

May 7, 2026, 4:00 PM EDT - 3 months ago

Kodiak Sciences Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 3 months ago

Kodiak Sciences Quarterly report: Q1 2026

May 1, 2026, 12:23 AM EDT - 3 months ago

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Kodiak Sciences Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Kodiak Sciences Proxy statement: Proxy filing

2026-04-02T16:07:19.000Z - 4 months ago

Kodiak Sciences falls -8.7%

2026-04-01T16:27:41.000Z - 5 months ago

Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings

2026-04-01T15:15:17.000Z - 5 months ago

Kodiak Sciences reports Q4 EPS ($1.05) vs (84c) last year

2026-04-01T14:07:48.000Z - 5 months ago

Kodiak Sciences rises 10.7%

Mar 31, 2026, 4:45 PM EDT - 5 months ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Mar 31, 2026, 4:00 PM EDT - 5 months ago

Kodiak Sciences Annual report: Q4 2025

Mar 31, 2026, 4:00 PM EDT - 5 months ago

Kodiak Sciences Earnings release: Q4 2025

Mar 30, 2026, 10:00 AM EDT - 5 months ago

Kodiak Sciences: Road To $120

2026-03-27T13:29:25.000Z - 5 months ago

Kodiak Sciences price target raised to $80 from $50 at UBS

2026-03-27T10:05:12.000Z - 5 months ago

Kodiak Sciences price target raised to $58 from $38 at H.C. Wainwright

2026-03-26T18:10:55.000Z - 5 months ago

Kodiak Sciences price target raised to $56 from $39 at Jefferies

Mar 26, 2026, 12:33 PM EDT - 5 months ago

Kodiak Sciences stock soars over 60%: what's behind the sharp rally

2026-03-26T13:00:50.000Z - 5 months ago

Morning Movers: Kodiak Sciences skyrockets following GLOW2 study results

CMC CRBG DBI EQH LOVE MLKN NAVN

Mar 26, 2026, 8:12 AM EDT - 5 months ago

Kodiak Sciences shares surge after eye drug succeeds in late-stage study

Mar 26, 2026, 6:00 AM EDT - 5 months ago

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Kodiak Sciences Slides: Corporate presentation

Feb 4, 2026, 7:00 AM EST - 7 months ago

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

Jan 22, 2026, 10:26 AM EST - 7 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX LITE

Jan 12, 2026, 4:30 PM EST - 7 months ago

Kodiak Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 7 months ago

Kodiak Sciences Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:19 PM EST - 8 months ago

Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:26 PM EST - 8 months ago

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 16, 2025, 10:55 PM EST - 8 months ago

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 8 months ago

Kodiak Sciences Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 3:00 PM EST - 9 months ago

Kodiak Sciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 17, 2025, 11:30 AM EST - 9 months ago

Kodiak Sciences Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 11:30 AM EST - 9 months ago

Kodiak Sciences Slides: FY 2025

Nov 13, 2025, 4:05 PM EST - 9 months ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 13, 2025, 4:00 PM EST - 9 months ago

Kodiak Sciences Earnings release: Q3 2025

Nov 13, 2025, 4:00 PM EST - 9 months ago

Kodiak Sciences Quarterly report: Q3 2025

Nov 12, 2025, 5:48 PM EST - 10 months ago

Kodiak Sciences to Present at Upcoming Investor Conferences

Nov 5, 2025, 7:00 AM EST - 10 months ago

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

Oct 31, 2025, 12:01 PM EDT - 10 months ago

The Big 3: GOOGL, KOD, FTK

GOOG GOOGL FTK

Sep 15, 2025, 7:00 AM EDT - 1 year ago

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

Aug 27, 2025, 10:40 AM EDT - 1 year ago

Harbour BioMed Reports 2025 Interim Results

Aug 19, 2025, 2:18 PM EDT - 1 year ago

Kodiak Sciences to Present at American Chemical Society Fall 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Kodiak Sciences Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Kodiak Sciences Earnings release: Q2 2025

Jul 16, 2025, 1:00 PM EDT - 1 year ago

Kodiak Sciences Transcript: R&D Day 2025

Jul 16, 2025, 1:00 PM EDT - 1 year ago

Kodiak Sciences Slides: FY 2025

Jul 10, 2025, 8:00 AM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

Jun 25, 2025, 4:45 PM EDT - 1 year ago

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

Jun 5, 2025, 9:20 AM EDT - 1 year ago

Kodiak Sciences Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 9:32 PM EDT - 1 year ago

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 22, 2025, 4:00 PM EDT - 1 year ago

Kodiak Sciences Quarterly report: Q1 2025

May 22, 2025, 4:00 PM EDT - 1 year ago

Kodiak Sciences Earnings release: Q1 2025

May 14, 2025, 4:15 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 1, 2025, 11:43 PM EDT - 1 year ago

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Kodiak Sciences Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Kodiak Sciences Proxy statement: Proxy Filing

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 10:30 AM EDT - 1 year ago

Kodiak Sciences Annual report: Q4 2024

Mar 27, 2025, 10:30 AM EDT - 1 year ago

Kodiak Sciences Earnings release: Q4 2024

Mar 10, 2025, 4:39 PM EDT - 1 year ago

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Feb 4, 2025, 7:30 AM EST - 1 year ago

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

Kodiak Sciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

Kodiak Sciences Slides: FY 2025

Jan 7, 2025, 6:00 AM EST - 1 year ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 2:35 PM EST - 1 year ago

Kodiak Sciences Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 21, 2024, 4:00 AM EST - 1 year ago

Kodiak Sciences Transcript: Jefferies London Healthcare Conference 2024

Nov 14, 2024, 4:01 PM EST - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 14, 2024, 4:00 PM EST - 1 year ago

Kodiak Sciences Earnings release: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

Kodiak Sciences Quarterly report: Q3 2024

Nov 11, 2024, 6:15 AM EST - 1 year ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Oct 14, 2024, 5:35 PM EDT - 2 years ago

Kodiak Sciences to Present at Innovate Retina 2024

Sep 23, 2024, 10:30 AM EDT - 2 years ago

Kodiak Sciences Transcript: R&D Day 2024

Sep 23, 2024, 10:30 AM EDT - 2 years ago

Kodiak Sciences Slides: FY 2024

Sep 23, 2024, 6:00 AM EDT - 2 years ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 17, 2024, 4:05 PM EDT - 2 years ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Aug 14, 2024, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

Aug 14, 2024, 4:00 PM EDT - 2 years ago

Kodiak Sciences Quarterly report: Q2 2024

Aug 14, 2024, 4:00 PM EDT - 2 years ago

Kodiak Sciences Earnings release: Q2 2024

Jun 13, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Transcript: Jefferies 2024 Global Healthcare Conference

Jun 6, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Slides: FY 2024

May 29, 2024, 4:36 PM EDT - 2 years ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 15, 2024, 4:15 PM EDT - 2 years ago

Kodiak Sciences Quarterly report: Q1 2024

May 15, 2024, 4:15 PM EDT - 2 years ago

Kodiak Sciences Earnings release: Q1 2024

May 15, 2024, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 13, 2024, 7:32 PM EDT - 2 years ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 2, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Kodiak Sciences Proxy statement: Proxy Filing

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Earnings Call Transcript: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Annual report: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Earnings release: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Slides: Q4 2023

Mar 28, 2024, 6:30 AM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 26, 2024, 6:15 AM EDT - 2 years ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Jan 30, 2024, 6:30 AM EST - 2 years ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 4, 2024, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Swift_Trades Aug. 20 at 3:25 AM

1 · Reply

spinusn27 Aug. 19 at 11:57 AM

$KOD $MRNA could be us in September. Good luck everyone. Lots of us have been here since $2.

0 · Reply

Stekli27 Aug. 18 at 4:00 PM

$KOD I expect some de-risking into DAYBREAK, just like we saw before the GLOW2 readout. If DAYBREAK comes in positive, I think this thing can explode..

1 · Reply

BB_88_ Aug. 17 at 3:37 PM

$KOD short tight stop day trade only

0 · Reply

Stekli27 Aug. 17 at 3:10 PM

1 · Reply

BeeDecay Aug. 17 at 11:49 AM

3 · Reply

BB_88_ Aug. 14 at 7:02 PM

$KOD expect fade in to close but could be wrong

0 · Reply

Stekli27 Aug. 14 at 6:34 PM

1 · Reply

Ntense Aug. 14 at 2:01 PM

$KOD down 15% in a week on no news? Good opportunity to add.

0 · Reply

Stekli27 Aug. 14 at 1:44 PM

$KOD time to add more 👀

0 · Reply

Ecolispewy Aug. 13 at 10:22 PM

$KOD Cash runway still looks good. No excessive dilution. Data releases still on track. Tomorrow morning trading shenanigans….

0 · Reply

Merlintrader Aug. 13 at 9:42 PM

Kodiak Sciences (Nasdaq: $KOD) Stock Hub: PEAK First Cohort Fully Enrolled, Zenkuda, DAYBREAK and the 2026 Retina Catalyst Map https://www.merlintrader.com/kodiak-sciences-stock-hub/

0 · Reply

BB_88_ Aug. 13 at 7:59 PM

$KOD of course the one day I don’t short haha I did buy end of day 39.65 and sold 40.1 it’s something

0 · Reply

tahloolaaa Aug. 11 at 2:22 PM

$KOD I wonder why they are starting the dme phase 3 with ksi501 now?

1 · Reply

BB_88_ Aug. 10 at 6:13 PM

$KOD usually spikes and pharma up today - bought some here

0 · Reply

eganon69 Aug. 9 at 5:50 PM

$KOD LARGE C&H Breakout on W chart as well as smaller C&H breakout on D chart with $45.10 as Resistance now acting as Support. Friday was 2nd day close >$45.10. LARGE C&H TP = $88.41

0 · Reply

Merlintrader Aug. 7 at 2:50 PM

$KOD DAYBREAK Phase 3 topline data in wet AMD — expected September 2026 https://www.merlintrader.com/kodiak-sciences-stock-hub/

0 · Reply

DanFitz Aug. 7 at 12:52 AM

Here's your trade on Kodiak $KOD https://youtu.be/7jfj7zZpnSA

0 · Reply

Ecolispewy Aug. 6 at 9:33 PM

$KOD 13+ days to cover shorts out at these volumes and long conviction pushing.

0 · Reply

Ecolispewy Aug. 6 at 9:00 PM

$KOD need more volume

0 · Reply

RainyDayFund Aug. 6 at 8:58 PM

$KOD Go Baby!

0 · Reply

Stekli27 Aug. 6 at 4:32 PM

$KOD just waiting for the happy hour 🍻

0 · Reply

Market Cap	2.55B
Revenue (ttm)	0.00
Net Income (ttm)	-229.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	595,800
Avg Vol	702,672
Day's Range	N/A - N/A
Shares Out	62.85M
Stochastic %K	35%
Beta	2.21
Analysts	Strong Sell
Price Target	$61.67